We are proud to mark a significant milestone: HALO AP® earned the highest overall customer rating in the 2026 KLAS Global Software report for digital pathology. Because KLAS distinction is driven entirely by direct customer feedback, this recognition reflects the real-world performance, reliability, and impact of our platform in daily pathology practice.
KLAS Recognition as a Catalyst for What Comes Next Read More »
Albuquerque, NM, February 12, 2026 – Indica Labs, the world’s leading provider of AI-powered digital pathology solutions, today announced recognition by KLAS for top customer-rated performance in the European digital pathology market.
HALO AP® is Now Rated in Best in KLAS®: Earning ‘A’ Grades in All Categories Read More »
Albuquerque, NM, February 10, 2025 – Indica Labs, the world’s leading provider of AI-powered digital pathology solutions, today announced the expansion of its macrodissection portfolio with the launch of Breast Macrodissect AI . The suite now includes advanced algorithms for non-small cell lung cancer (NSCLC), colorectal cancer (CRC), and breast cancer, with prostate cancer planned for release in early 2026.
Albuquerque, NM, December 17, 2025 – Indica Labs, the global leader in AI-powered digital pathology, announced today that clinical revenue growth rate for HALO AP® is up 260% since 2023 and recurring revenue for 2025 shows a 200% increase year-over-year, reinforcing its position as a market leader in digital pathology diagnostics.
Indica Labs Reports 260% Clinical Revenue Growth and Expansion into New Global Markets Read More »
ALBUQUERQUE, NM, and VISTA, CA, December 3, 2025 – Indica Labs, the global leader of AI-powered digital pathology, and Leica Biosystems, a global leader in anatomic and digital pathology solutions, announced today that the Food and Drug Administration (FDA) has issued a 510(k) clearance for the enterprise digital pathology platform HALO AP Dx in conjunction with Leica Biosystems Aperio GT 450 DX Scanner for in-vitro diagnostic use.
Albuquerque, NM, April 30, 2025 – Indica Labs, the leading provider of AI-powered digital pathology solutions, announces today an update to their Breast IHC AI suite, an image analysis tool used for the quantification of HER2, ER, PR, and Ki67 within AI-identified, tumor regions, of breast cancer tissue specimens. The HER2 algorithm will now include functionality for the detection of low and ultralow HER2 expression in breast cancer.
